EUVIMEDOpdag EUVIMED
Systematische ÜbersichtMetaanalyse

Vortioxetine for depression in adults: A systematic review and dose–response meta‐analysis of randomized controlled trials

Xin Yang, Shuping Fang, Wenqi Lyu iD, Yongbo Hu, Huifang Xu, Xiao Jiang, Yurou Zhao, Yuwei Zhang, Jin Li, Weihong Kuang iD

Psychiatry and Clinical Neurosciences · 2024-09 · 78 (9) · 536-545

DOI: 10.1111/pcn.13709 ↗

At a glance

Systematische Übersicht in Psychiatry and Clinical Neurosciences, published online on 2024-07-03. Written by Xin Yang and 9 co-authors. Institution: Department of Mental Health Center, West China Hospital of Sichuan University, Chengdu, China. Major MEDLINE topics: Antidepressive Agents, Major Depressive Disorder, Dose-Response Relationship, Drug, Vortioxetine. Cited 13 times so far (Crossref); 54 references. Funded by: The National Key R&D Program of China, 1.3.5 Program of West China Hospital, National Key Research and Development Program of China.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aim

Major depressive disorder (MDD) is a prevalent psychiatric condition and vortioxetine offers promising antidepressant effects due to its unique pharmacological profile. However, the dose–response relationships of vortioxetine for MDD is not well established. We aimed to conduct dose–response meta‐analyses to fill this gap.

Methods

We systematically searched multiple electronic databases for randomized controlled trials of vortioxetine for MDD, with the last search conducted on 08 February, 2024. The dose–response relationship was evaluated using a one‐stage random‐effects dose–response meta‐analysis with restricted cubic spline model. The primary outcome was efficacy (mean change in depression scale score), with secondary outcomes including response, dropout for any reasons (acceptability), dropout for adverse events (tolerability), and any adverse events (safety).

Results

The dose–response meta‐analysis comprised 16 studies, with 4,294 participants allocated to the vortioxetine group and 2,299 participants allocated to the placebo group. The estimated 50% effective dose was 4.37 mg/day, and the near‐maximal effective dose (95% effective dose) was 17.93 mg/day. Visual inspection of the dose‐efficacy curve suggests that a plateau possibly had not been reached yet at 20 mg/day. Acceptability, tolerability and safety decreased as the dose increased. Subgroup analysis indicated that no significant differences were observed in acceptability, tolerability and safety among the dosage groups.

Conclusions

Vortioxetine may potentially provide additional therapeutic benefits when exceeding the current licensed dosage without significantly impacting safety. Conducting clinical trials exceeding the current approved dosage appears necessary to fully comprehend its efficacy and risk.

Subjects

MeSH terms (MEDLINE)

Antidepressive AgentsMajor Depressive DisorderDose-Response Relationship, DrugVortioxetineAdultHumansRandomized Controlled Trials as Topic

Author keywords

dose–response relationshipsefficacymajor depressive disordermeta‐analysisvortioxetine

Substances

Antidepressive AgentsVortioxetine

Authors and institutions

  • Department of Mental Health Center, West China Hospital of Sichuan University, Chengdu, China.
  • Department of Division of Neurology and Psychiatry, West China Xiamen Hospital of Sichuan University, Xiamen, China.
  • Department of Radiology, Huaxi MR Research Center (HMRRC), West China Hospital of Sichuan University, Chengdu, China.
  • Department of Geriatric Psychiatry, The Fourth People's Hospital of Chengdu, Chengdu, China.
  • Department of Psychiatry, Ziyang Psychosis Hospital, Ziyang, China.
  • Department of Geriatric, Chengdu Second People's Hospital, Chengdu, China.

ORCID profiles: Wenqi Lyu, Weihong Kuang

Funding

  • The National Key R&D Program of China
  • 1.3.5 Program of West China Hospital
  • National Key Research and Development Program of China

Cite

APA

Yang, X., Fang, S., Lyu, W., Hu, Y., Xu, H., Jiang, X., Zhao, Y., Zhang, Y., Li, J., & Kuang, W. (2024). Vortioxetine for depression in adults: A systematic review and dose–response meta‐analysis of randomized controlled trials. Psychiatry and Clinical Neurosciences, 78(9), 536-545. https://doi.org/10.1111/pcn.13709

Vancouver

Yang X, Fang S, Lyu W, Hu Y, Xu H, Jiang X, et al. Vortioxetine for depression in adults: A systematic review and dose–response meta‐analysis of randomized controlled trials. Psychiatry and Clinical Neurosciences. 2024;78(9):536-545. doi:10.1111/pcn.13709

BibTeX
@article{Yang2024,
  author = {Yang, Xin and Fang, Shuping and Lyu, Wenqi and Hu, Yongbo and Xu, Huifang and Jiang, Xiao and Zhao, Yurou and Zhang, Yuwei and Li, Jin and Kuang, Weihong},
  title = {Vortioxetine for depression in adults: A systematic review and dose–response meta‐analysis of randomized controlled trials},
  journal = {Psychiatry and Clinical Neurosciences},
  year = {2024},
  volume = {78},
  number = {9},
  pages = {536--545},
  doi = {10.1111/pcn.13709}
}
Start for free →